Investor Relations

NYSE: NVRO

Price

86.49 +0.00 ( +0% ) 5:00 8-22-17 Pricing delayed 20 minutes

Volume 351,600

Recent News

See All
August 7, 2017 Nevro Reports Second Quarter 2017 Financial Results
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the three and six months ended June 30, 2017 . Second Quarter Highlights: Achieved revenue of $78.0 million in the second quarter of 2017, an increase of 41% as reported, over the same period of the prior year U.S. revenue of $63.0 million in the second quarter of 2017, an increase of 55% over the prior year International revenue of $15.0 million in the second quarter of 2017, an increase of 4% in constant currency and 1% on an as-reported basis, both over the same period of the prior year SENZA-RCT 24-month outcomes publication selected as the Top Pain Paper of the Year by Neurosurgery , the official journal of the Congress of Neurological Surgeons (CNS) Initiated SENZA-PDN, the largest randomized controlled trial evaluating spinal cord stimulation (SCS) for the treatment of painful diabetic neuropathy...
July 26, 2017 Nevro to Present at the Canaccord Genuity Growth Conference
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that its management will be presenting at the Canaccord Genuity Growth Conference on Wednesday, August 9, 2017 in Boston. Nevro management is scheduled to present at 1:30 p.m. ET.  The presentation will be accessible via a live audio webcast, accessible in the "Investors" section of the company's website at: http://www.nevro.com/investors. Following the presentation, an archived copy will be available on the Investor Events and Presentations webpage of the Company's website. About Nevro Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform...
July 24, 2017 Nevro to Report Operating Results for the Second Quarter 2017
Nevro to Host Conference Call on Monday, August 7, 2017 at 1:30 p.m. PT / 4:30 p.m. ET Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it will release financial results for the second quarter of 2017 after market close on Monday, August 7, 2017 . Company management will host a conference call beginning at 1:30 p.m. Pacific Time ( 4:30 p.m. Eastern Time ) on Monday, August 7, 2017 . Investors interested in listening to the conference call may do so by dialing (877) 648-7976 for U.S. callers, or (617) 826-1698 for international callers (Conference ID: 52275180), or from the webcast on the "Investors" section of the Company's website at www.nevro.com/investors. Following the call, a replay will be available on the Investor Events and Presentations webpage of the Company's website. About Nevro Headquartered in Redwood City, California , Nevro is a global medical device...

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza System is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, HF10, Nevro, and the Nevro logo are trademarks of Nevro.

Senza, HF10, Nevro, and the Nevro logo are trademarks of Nevro Corp.